|Articles|April 7, 2004
Study: Growth factor inhibitors market to triple
An aging patient population and diseases such as macular degeneration will boost the worldwide market for drugs that inhibit growth factors and angiogenesis from under $4 billion to more than $13 billion in the next five years, according to a study released March 24 by an independent market research firm.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























